logo-loader
viewVolitionRx

Full interview: VolitionRx achieves 'massive breakthrough' in its Nu.Q Capture cancer diagnostic technology

VolitionRx Limited (NYSEAMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the cancer diagnostic company has achieved a 'massive breakthrough' in the development of its Nu.Q Capture cancer-detection technology, which is the ability to enrich nucleosomes.

Reynolds says enriching nucleosomes effectively 'sweeps away' the background noise, achieving a better signal-to-noise ratio, which creates a potential licensing opportunity from other companies in the liquid biopsy space that specialize in sequencing.

Quick facts: VolitionRx

Price: 4.87 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $200.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx acquires epigenetic reagent company Octamer GmbH

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds talks through the rationale for its acquisition of epigenetic reagent company Octamer GmbH. Reynolds says they're paying around €650,000 euros ($725,000) in cash and stock and the deal is expected to close in January 2020. 

on 12/20/2019

2 min read